Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTGGF Bitcoin Group	$63.22	$63.22	$63.22 ▼ $63.22	$24.43B	0.26	279 shs	1 shs
CRL Charles River Laboratories International	$157.12 -0.2%	$139.86	$91.86 ▼ $254.15	$7.72B	1.49	1.03 million shs	247,085 shs
EXAS Exact Sciences	$52.82 -1.9%	$53.58	$39.97 ▼ $72.83	$9.96B	0.95	2.58 million shs	1.67 million shs
INCY Incyte	$68.46 +0.4%	$65.34	$53.56 ▼ $83.95	$13.25B	0.68	1.97 million shs	1.27 million shs
IQV IQVIA	$164.24 -0.2%	$150.59	$134.65 ▼ $252.88	$28.41B	1.3	1.65 million shs	674,106 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTGGF Bitcoin Group	0.00%	0.00%	0.00%	0.00%	+3.36%
CRL Charles River Laboratories International	-0.24%	+3.54%	+13.27%	+14.73%	-21.99%
EXAS Exact Sciences	-1.94%	+1.94%	-3.69%	+24.12%	+22.29%
INCY Incyte	+0.43%	-3.32%	+2.01%	+13.01%	+18.73%
IQV IQVIA	-0.31%	+3.95%	+15.06%	+6.22%	-20.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BTGGF Bitcoin Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRL Charles River Laboratories International	4.0648 of 5 stars	2.1	2.0	0.0	4.7	2.2	2.5	1.9
EXAS Exact Sciences	4.9183 of 5 stars	4.5	5.0	0.0	4.7	2.8	2.5	0.6
INCY Incyte	4.3494 of 5 stars	2.1	3.0	0.0	2.8	2.5	2.5	3.1
IQV IQVIA	4.9145 of 5 stars	4.4	2.0	0.0	4.6	3.2	1.7	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BTGGF Bitcoin Group	0.00	N/A	N/A	N/A
CRL Charles River Laboratories International	2.19	Hold	$171.85	9.37% Upside
EXAS Exact Sciences	2.95	Moderate Buy	$70.40	33.30% Upside
INCY Incyte	2.22	Hold	$74.53	8.87% Upside
IQV IQVIA	2.75	Moderate Buy	$226.32	37.80% Upside

Current Analyst Ratings Breakdown

Latest IQV, BTGGF, CRL, EXAS, and INCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	EXAS Exact Sciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $65.00
6/23/2025	INCY Incyte	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Sector Perform ➝ Sector Perform	$67.00
6/16/2025	INCY Incyte	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$75.00 ➝ $107.00
6/3/2025	INCY Incyte	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/3/2025	INCY Incyte	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$61.00
5/27/2025	INCY Incyte	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$72.00 ➝ $73.00
5/23/2025	IQV IQVIA	Redburn Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$188.00
5/23/2025	CRL Charles River Laboratories International	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$188.00 ➝ $182.00
5/22/2025	IQV IQVIA	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
5/19/2025	IQV IQVIA	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$232.00 ➝ $177.00
5/15/2025	IQV IQVIA	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$210.00 ➝ $190.00

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BTGGF Bitcoin Group	N/A	N/A	N/A	N/A	N/A	N/A
CRL Charles River Laboratories International	$4.05B	1.91	$21.64 per share	7.26	$67.80 per share	2.32
EXAS Exact Sciences	$2.76B	3.61	$5.52 per share	9.56	$12.98 per share	4.07
INCY Incyte	$4.24B	3.12	$0.56 per share	123.14	$17.90 per share	3.82
IQV IQVIA	$15.41B	1.84	$16.57 per share	9.91	$33.43 per share	4.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BTGGF Bitcoin Group	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CRL Charles River Laboratories International	$22.20M	-$0.65	N/A	14.28	5.33	-0.66%	15.19%	6.93%	8/6/2025 (Estimated)
EXAS Exact Sciences	-$1.03B	-$5.51	N/A	105.63	11.50	-36.06%	-3.75%	-1.68%	7/30/2025 (Estimated)
INCY Incyte	$32.62M	$0.32	213.94	10.47	0.57	0.48%	2.77%	1.77%	7/29/2025 (Estimated)
IQV IQVIA	$1.37B	$7.34	22.38	13.46	1.83	8.61%	29.16%	6.96%	7/28/2025 (Estimated)

Latest IQV, BTGGF, CRL, EXAS, and INCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	EXAS Exact Sciences	-$0.04	N/A	N/A	N/A	$774.43 million	N/A
7/29/2025	Q2 2025	INCY Incyte	$1.38	N/A	N/A	N/A	$1.15 billion	N/A
7/28/2025	Q2 2025	IQV IQVIA	$2.76	N/A	N/A	N/A	N/A	N/A
5/7/2025	Q1 2025	CRL Charles River Laboratories International	$2.06	$2.34	+$0.28	$0.50	$942.34 million	$984.17 million
5/6/2025	Q1 2025	IQV IQVIA	$2.63	$2.70	+$0.07	$1.40	$3.77 billion	$3.83 billion
5/1/2025	Q1 2025	EXAS Exact Sciences	-$0.37	-$0.21	+$0.16	-$0.54	$688.58 million	$706.79 million
4/29/2025	Q1 2025	INCY Incyte	$1.01	$1.16	+$0.15	$0.80	$996.17 million	$1.05 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BTGGF Bitcoin Group	N/A	N/A	N/A	N/A	N/A
CRL Charles River Laboratories International	N/A	N/A	N/A	N/A	N/A
EXAS Exact Sciences	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
IQV IQVIA	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BTGGF Bitcoin Group	N/A	N/A	N/A
CRL Charles River Laboratories International	0.78	1.43	1.16
EXAS Exact Sciences	0.97	2.73	2.38
INCY Incyte	0.01	2.04	2.00
IQV IQVIA	2.19	0.82	0.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BTGGF Bitcoin Group	N/A
CRL Charles River Laboratories International	98.91%
EXAS Exact Sciences	88.82%
INCY Incyte	96.97%
IQV IQVIA	89.62%

Insider Ownership

Company	Insider Ownership
BTGGF Bitcoin Group	N/A
CRL Charles River Laboratories International	1.30%
EXAS Exact Sciences	1.20%
INCY Incyte	17.80%
IQV IQVIA	1.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BTGGF Bitcoin Group	35	386.49 million	N/A	Not Optionable
CRL Charles River Laboratories International	20,100	49.12 million	48.48 million	Optionable
EXAS Exact Sciences	7,000	188.64 million	186.37 million	Optionable
INCY Incyte	2,617	193.57 million	159.12 million	Optionable
IQV IQVIA	88,000	173.00 million	170.23 million	Optionable

IQV, BTGGF, CRL, EXAS, and INCY Headlines

Recent News About These Companies

Nichols & Pratt Advisers LLP MA Buys 2,044 Shares of IQVIA Holdings Inc. (NYSE:IQV)

4 hours ago | marketbeat.com

Lupin launches generic version of anticholinergic medication Ipratropium bromide in United States

July 4 at 6:59 AM | msn.com

Lupin launches Ipratropium Bromide nasal spray in US

July 4 at 6:59 AM | economictimes.indiatimes.com

IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Sumitomo Mitsui DS Asset Management Company Ltd

July 2 at 6:37 AM | marketbeat.com

IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Vontobel Holding Ltd.

July 2 at 6:18 AM | marketbeat.com

New York State Teachers Retirement System Sells 7,831 Shares of IQVIA Holdings Inc. (NYSE:IQV)

July 2 at 5:16 AM | marketbeat.com

Mirae Asset Global Investments Co. Ltd. Sells 1,592 Shares of IQVIA Holdings Inc. (NYSE:IQV)

July 2 at 4:31 AM | marketbeat.com

Is IQVIA Hldgs Gaining or Losing Market Support?

July 1 at 12:36 AM | benzinga.com

Understanding the FDA’s AI Guidance in Pharmacovigilance

July 1 at 12:36 AM | biospace.comB

Lupin shares in focus after FDA nod for post-eye surgery drug Loteprednol Etabonate Gel

July 1 at 12:36 AM | msn.com

IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025

July 1 at 7:00 AM | businesswire.com

Sequoia Financial Advisors LLC Sells 79,065 Shares of IQVIA Holdings Inc. (NYSE:IQV)

July 1 at 4:10 AM | marketbeat.com

Alembic Pharmaceuticals shares jump 14% on USFDA approval for cancer drug

June 30, 2025 | msn.com

Navigating AI’s promise and pitfalls in DTC advertising

June 30, 2025 | mmm-online.comM

Alembic Pharma shares surge as much as 12% on Monday; Here's why

June 30, 2025 | cnbctv18.comC

Alembic Pharma jumps after receiving USFDA nod for Doxorubicin Hydrochloride Injection

June 30, 2025 | msn.com

Alembic Pharmaceuticals gets USFDA nod for generic cancer treatment injection

June 30, 2025 | thehindubusinessline.com

Alembic Pharma Shares Soar 14%, Gets USFDA Nod For Key Cancer Drug

June 30, 2025 | msn.com

Alembic Pharmaceuticals Gains USFDA Nod for Cancer Fighting Injection

June 30, 2025 | devdiscourse.comD

Analysts Set IQVIA Holdings Inc. (NYSE:IQV) Price Target at $226.32

June 30, 2025 | americanbankingnews.com

KBC Group NV Has $106.44 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

June 29, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
By Leo Miller | June 25, 2025
View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
Texas Instruments Stock: Congress Likes It, Should You Too?
By Thomas Hughes | June 24, 2025
View Texas Instruments Stock: Congress Likes It, Should You Too?

IQV, BTGGF, CRL, EXAS, and INCY Company Descriptions

Bitcoin Group OTCMKTS:BTGGF

$63.22 0.00 (0.00%)

As of 07/3/2025

Bitcoin Group SE, an investment holding company, engages in the cryptocurrency and blockchain businesses worldwide. The company operates a trading platform for the digital currency bitcoin under the Bitcoin.de. It also provides financial services. The company was founded in 2008 and is based in Herford, Germany. Bitcoin Group SE is a subsidiary of Priority AG.

Charles River Laboratories International NYSE:CRL

$157.12 -0.37 (-0.23%)

Closing price 07/3/2025 03:30 PM Eastern

Extended Trading

$157.12 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Exact Sciences NASDAQ:EXAS

$52.82 -1.05 (-1.94%)

Closing price 07/3/2025 03:12 PM Eastern

Extended Trading

$52.82 0.00 (0.00%)

As of 07/3/2025 04:33 PM Eastern

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Incyte NASDAQ:INCY

$68.46 +0.29 (+0.43%)

Closing price 07/3/2025 03:25 PM Eastern

Extended Trading

$67.23 -1.23 (-1.80%)

As of 07/3/2025 04:18 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

IQVIA NYSE:IQV

$164.24 -0.41 (-0.25%)

Closing price 07/3/2025 03:30 PM Eastern

Extended Trading

$163.14 -1.11 (-0.67%)

As of 07/3/2025 04:58 PM Eastern

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time